Study Compares Performance of Masimo Acoustic Respiration Rate (RRa®) and Nellcor Plethysmographic Respiration Rate in Volunteers
Masimo (NASDAQ: MASI) announced today that researchers at the Tokyo Women’s Medical University, Department of Anesthesiology, in Japan have published a study investigating the measurement of respiration rate in volunteers. Masimo acoustic respiration rate (Masimo), using the Masimo Radical-7® Pulse CO-Oximeter®, was studied alongside Nellcor plethysmographic respiration rate (Nellcor), using the Nellcor PM1000N.1
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170731005381/en/
Masimo Radical-7® Pulse CO-Oximeter® with RAS-125c Respiratory Acoustic Sensor (Photo: Business Wire)
Dr. Kitsiripant and colleagues enrolled 50 healthy adult volunteers in the study. Respiration rate, pulse rate, and oxygen saturation (SpO2) values were measured using the two technologies: Nellcor respiration rate, pulse rate, and SpO2 on PM1000N (version 184.108.40.206) were measured using an SpO2 adhesive sensor on the left index finger; Masimo respiration rate on Radical-7 (V.7910, processor V1.3.06i) was measured using the RAS-125c (rev D) acoustic sensor on the left side of the neck, with an R1-25L adhesive sensor on the right index finger measuring Masimo pulse rate and SpO2.
Both devices were configured to alarm in the event of respiratory pause (Masimo) or low respiration rate (Nellcor) for 30 seconds, respiration rate under 10 breaths/minute, and SpO2 of 90% or below. The volunteers were required to breathe at a rate of 12 breaths/minute for 3 minutes, then hold their breath until one of the device’s respiratory pause/low respiration rate alarms was triggered, then resume breathing. Because of the difficulty for some volunteers of completely stopping airflow for 30 seconds, a smaller group of 10 volunteers was recruited to perform the same procedure but with respiratory pause/low respiration rate alarms set to 15 seconds.
Of the 143 procedures in which breathing was successfully held for more than 30 seconds, Masimo alarmed 114 times and Nellcor alarmed 15 times. The average time to alarm for Masimo was 35 seconds and for Nellcor, 59 seconds. Most of the alarms for Nellcor followed from SpO2 being < 90%, whereas most for Masimo were caused by respiration rate < 10 breaths/minute (which tended to occur prior to the drop in SpO2). Of the 29 procedures in which breathing was held for 15 seconds, Masimo alarmed 29 times, with an average time to alarm of 21 seconds, and Nellcor did not alarm at all.
The researchers concluded that Masimo acoustic respiration rate provided faster detection of respiratory pause than Nellcor, but it should be noted as a limitation of the study that the measurements were taken using volunteer participants who maintained a fixed breathing rate and then abruptly held their breath.
rainbow Acoustic Monitoring® sensors and cables are indicated for the continuous, noninvasive monitoring of respiratory rate (RRa®). The RAS-125c sensor is indicated for adult and pediatric patients, in hospitals, hospital-type facilities, mobile and home environments.
@MasimoInnovates | #Masimo
- Kitsiripant C et al. Comparison of Nellcor™ PM1000N and Masimo Radical-7® for detecting apnea in volunteers. J Anesth. 9 July 2017. DOI: 10.1007/s00540-017-2385-4.
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,1 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™* in post-surgical wards, reduce rapid response activations and costs.3,4,5 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at 16 of the top 20 hospitals listed in the 2016-17 U.S. News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), and more recently, Oxygen Reserve Index™ (ORi™), in addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor, iSpO2 ® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
ORi has not received FDA 510(k) clearance and is not available for sale in the United States.
*The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;338.
- Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
- Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
- McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
- Estimate: Masimo data on file.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo RRa®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo RRa, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Evan Lamb, 949-396-3376
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Gilead Sciences Announces Senior Management Change22.2.2018 22:00 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that James Meyers, Executive Vice President, Commercial Operations, will retire. Mr. Meyers joined Gilead in 1996 as a regional sales director and was appointed to his current role in 2016. Following a brief family leave earlier this year, Mr. Meyers made the decision to retire from his full-time role effective immediately. Mr. Meyers will remain with the company in an advisory capacity, to consult on priority projects and to assist with identifying his successor and facilitating the transition. The company will begin a search for his successor in the coming weeks. “Jim has been instrumental in leading Gilead through a period of tremendous growth and change, and he has built an exceptional team. I am confident in the ability of that team to execute against our ambitious goals and grateful to Jim for his commitment to assist us through this transition,” said John Milligan, PhD, President and Chief Executive Officer, Gilead Sciences. “
Trump International Hotel Washington, D.C. Announced as First Forbes Five Star Hotel in Downtown Washington, D.C.22.2.2018 19:21 | Pressemelding
Trump International Hotel Washington, D.C. announces today that it has been awarded the 2018 Forbes Five-Star recognition, making it the first hotel to receive the prestigious distinction in Downtown Washington D.C. Forbes Travel Guide, the global authority on luxury travel, sends anonymous professional inspectors around the world to assess hotels, restaurants and spas against up to 800 objective standards focused on service and facilities. Just opened a short fifteen months ago, the property is located on Pennsylvania Avenue in the center of the city at the site of the Old Post Office. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222006277/en/ Trump International Hotel Washington, D.C. (Photo: Business Wire) Mickael Damelincourt, Managing Director, oversaw the recruitment and selection of the executives whose teams would lead the hotel through the construction and opening phases, instilling a commitment to the highest l
Entrust Datacard and Infineon Partner to Reduce Complexities with Securing IoT Deployments22.2.2018 18:30 | Pressemelding
Entrust Datacard, a leading provider of trusted identity and secure transaction technology solutions, today announced it has joined the Infineon Security Partner Network (ISPN). The ISPN is part of Infineon Technologies AG, a leading provider of semiconductor solutions used in automotive, industrial, computing and Internet of Things applications. The ISPN is composed of associated and preferred security partners who are proven experts in security consulting, security solution provisioning, electronic design, systems integration and trust services management. The new partnership will apply the Entrust Datacard™ ioTrust™ Security Solution that uses identity-based technology to help securely connect the people, applications and devices that power the connected world. The tiered software uses sophisticated cryptographic technology to provide identity issuance, management and data security of connected things within industrial environments. As a global leader in Trusted Platform Modules (TP
Blue Danube Systems Joins xRAN Forum as a Massive MIMO System Supplier Fully Committed to Open Interfaces22.2.2018 18:10 | Pressemelding
Blue Danube Systems, a provider of intelligent wireless access solutions that help mobile operators address the challenge of explosive data growth, today announced that it has joined the xRAN Forum (www.xran.org). The xRAN Forum was formed by several leading global mobile operators to develop, standardize and promote an open alternative to the traditionally closed, hardware-based RAN (Radio Access Network) architecture. Massive MIMO systems are widely recognized to be a critical element of future 5G wireless networks. Blue Danube’s unique approach to Massive MIMO, based on the company’s underlying High Definition Active Antenna Systems (HDAAS™) technology, not only delivers capacity gains in existing LTE networks with today’s smartphones but also enables intelligent analytics-based RF virtualization for multi-site network performance optimization. Blue Danube’s first Massive MIMO product, the BeamCraft™ 500, has been deployed at four FDD-LTE operators to date, interfacing to four diffe
Blue Danube Systems First to Demonstrate Benefits of FDD Massive MIMO in Clustered Multi-Sector Deployments22.2.2018 18:07 | Pressemelding
Blue Danube Systems, a provider of intelligent wireless access solutions that help mobile operators address the challenge of explosive data growth, today announced it has successfully expanded the commercial deployment of its massive MIMO solution to multiple clustered cell sites, demonstrating total capacity improvements for directly adjoining sectors on existing LTE networks using current smartphones. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222006158/en/ Blue Danube Systems First to Demonstrate Benefits of FDD Massive MIMO in Clustered Multi-Sector Deployments (Photo: Business Wire) Despite the prevalent view that Massive MIMO systems will be central to 5G networks, it has not been clearly proven that the technology is deployable beyond isolated high-demand sectors where effects such as adjacent cell interference must be addressed. In fact, common digital-only Massive MIMO implementations typically operate as clos
Avnet and IDEMIA Develop Highly Flexible ‘Plug & Play’ Cellular Connectivity Solution for IoT and Industry 4.0 Applications22.2.2018 16:08 | Pressemelding
Avnet (NYSE: AVT), a leading global technology distributor and IDEMIA (formerly known as OT-Morpho), the global leader in Augmented Identity, have joined forces to collaborate on the development of a new future-proof cellular connectivity solution that meets the growing communication requirements for Internet of Things (IoT) and Industry 4.0 applications. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005966/en/ (Photo: IDEMIA) The new ‘plug & play’ eUICC (embedded Universal Integrated Circuit Card) and SM-SR (Subscription Management Secure Routing) delivers product future-proofing capability to IoT application solution providers and other businesses. It provides them with the ability to easily choose a mobile network operator (MNO) without eventually having to manually change the embedded SIM card in their cellular connectivity-based devices, machines and sensors that are already deployed in the field. The product bund